Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Klotz, Luisa; Grützke, Berit; Eveslage, Maria; Deppe, Michael; Gross, Catharina C; Kirstein, Lucienne; Posevitz-Fejfar, Anita; Schneider-Hohendorf, Tilman; Schwab, Nicholas; Meuth, Sven G; Wiendl, Heinz

Klotz, Luisa; Grützke, Berit; Eveslage, Maria; Deppe, Michael; Gross, Catharina C; Kirstein, Lucienne; Posevitz-Fejfar, Anita; Schneider-Hohendorf, Tilman; Schwab, Nicholas; Meuth, Sven G; Wiendl, Heinz.

Afiliação

Klotz L; Department of neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, building A1, Münster, 48149, Germany. luisa.klotz@ukmuenster.de.
Grützke B; Department of neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, building A1, Münster, 48149, Germany. berit.gruetzke@gmail.com.
Eveslage M; Institute of biostatistics and clinical research, Westfaelische Wilhelms-University Münster, Münster, Germany. maria.eveslage@ukmuenster.de.
Deppe M; Department of neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, building A1, Münster, 48149, Germany. deppe@uni-muenster.de.
Gross CC; Department of neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, building A1, Münster, 48149, Germany. catharina.gross@ukmuenster.de.
Kirstein L; Department of neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, building A1, Münster, 48149, Germany. lucienne.kirstein@ukmuenster.de.
Posevitz-Fejfar A; Department of neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, building A1, Münster, 48149, Germany. anita.posevitz-fejfar@ukmuenster.de.
Schneider-Hohendorf T; Department of neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, building A1, Münster, 48149, Germany. tilman.schneider-hohendorf@ukmuenster.de.
Schwab N; Department of neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, building A1, Münster, 48149, Germany. nicholas.schwab@ukmuenster.de.
Meuth SG; Department of neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, building A1, Münster, 48149, Germany. sven.meuth@ukmuenster.de.
Wiendl H; Department of neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, building A1, Münster, 48149, Germany. heinz.wiendl@ukmuenster.de.

BMC Neurol ; 15: 96, 2015 Jun 23.

Article em En | MEDLINE | ID: mdl-26099927

Assuntos

Cloridrato de Fingolimode/uso terapêutico; Imageamento por Ressonância Magnética; Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico; Natalizumab/uso terapêutico; Progressão da Doença; Humanos; Estudos Prospectivos; Risco

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imageamento por Ressonância Magnética / Esclerose Múltipla Recidivante-Remitente / Cloridrato de Fingolimode / Natalizumab Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: BMC Neurol Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google